Health

Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older

DailyTrendDailyTrend
May 26, 2025 - 22:00
 0  0
Arcutis’ Zoryve (roflumilast) Topical Foam 0.3% Approved by U.S. FDA for the Treatment of Plaque Psoriasis in Adults and Adolescents Ages 12 and Older
WESTLAKE VILLAGE, Calif., May 22, 2025 (GLOBE NEWSWIRE) — Arcutis Biotherapeutics, Inc. (Nasdaq: ARQT), a commercial-stage biopharmaceutical company focused on developing meaningful innovations in immuno-dermatology, today announced the U.S...
Read More

What's Your Reaction?

Like Like 0
Dislike Dislike 0
Love Love 0
Funny Funny 0
Angry Angry 0
Sad Sad 0
Wow Wow 0
DailyTrend
DailyTrend

Related Posts

Why Wildfire Fighters Are Getting Dangerously Sick

Why Wildfire Fighters Are Getting Dangerously Sick

DailyTrend Aug 17, 2025  0  0

What to Know About Plague After a New Case in California

What to Know About Plague After a New Case in California

DailyTrend Aug 22, 2025  0  0

Early Alert: Cardiac Cannula Issue from Medtronic

Early Alert: Cardiac Cannula Issue from Medtronic

DailyTrend Aug 16, 2025  0  0

Hiker in Tennessee Who Picked Up a Venomous Snake Dies After Being Bitten

Hiker in Tennessee Who Picked Up a Venomous Snake Dies ...

DailyTrend Aug 17, 2025  0  0

Was Head-Binding an Ancient Way to Get Ahead?

DailyTrend Aug 22, 2025  0  0

FDA Approves Papzimeos (zopapogene imadenovec-drba) for the Treatment of Adults with Recurrent Respiratory Papillomatosis

FDA Approves Papzimeos (zopapogene imadenovec-drba) for...

DailyTrend Aug 18, 2025  0  0